Nordic Life Science 1
TOP STORIES BUSINESS A GREEMEN T Orion and Amneal
enter strategic partnership Orion has signed a longterm license agreement with Amneal to commercialize its generic products in Orion territories. Jeppe Øvlesen, CEO, SynAct Pharma B U S I NES S D E AL SYNACT PHARMA ACQUIRES TXP PHARMA TXP Pharma is a Swiss-incorporated biotech company researching and developing pharmaceutical drugs for the treatment of autoimmune and inflammatory diseases. THE PURCHASE PRICE consists of a fixed purchase price of 136 million SEK and a potential additional purchase price of 55 million SEK. The acquisition gives SynAct two platforms that complement each other and create a versatility to develop therapies to address the full range of inflammatory and autoimmune diseases. The aim is that SynAct will shortly have two projects in clinical development and another two in a relatively advanced pre10 | NORDICLIFESCIENCE.ORG clinical phase. In conjunction with the acquisition the board of directors of SynAct Pharma decided to carry out a directed share issue to companies controlled by Thomas von Koch and Christian Kinch. This will provide the company with 80 million SEK before transaction costs. The investment from von Koch and Kinch and the completion of the Directed Share Issue is not conditional on completion of the acquisition of TXP. ORION IS GRANTED exclusive license to commercialize and sell Amneal’s generic products in most parts of Europe, as well as in Australia and New Zealand. The initial portfolio will include a mix of generic products commercially available in the U.S., as well as selected pipeline products currently under development. Initial products will be registered throughout Europe, Australia and New Zealand starting in 2023, with launches expected over the coming years. Orion and Amneal will work together to develop and register products to Orion markets. “This agreement expands our footprint in the European generics market as well as in the Asia-Pacific region. In addition, it supports our growth strategy and is yet another fine example how Orion grows its business through high-quality strategic partnerships,” says Liisa Hurme, CEO, Orion. Liisa Hurme, CEO, Orion Pharma PHOTO SAMI TUORINIEMI